Highlights of first PDCO meeting of 2009

At its first meeting of the new year, the European Medicines Agency's (EMEA) Pediatric Committee (PDCO) adopted opinions agreeing pediatric  investigation plans (PIPs) for the following medicines:

- anastrozole from the UK's AstraZeneca, and iron, aqua carbonate  hydroxy oxo starch sucrose complex from Swiss drug major Novartis, in  the therapeutic area of endocrinology-gynecology-fertility-metabolism;

- an antigen of pre-pandemic strain A/Vietnam/1203/2004 propagated in  Vero cells from US health care firm Baxter, in the therapeutic area of  vaccines;